TACSTD2 and neoplasm: The in vivo analysis revealed that the incorporation of CD40 ligand significantly boosted the immunogenicity of Trop2-CD40L VLPs against lung cancer, resulting in more effective tumor control and an increased survival rate in Lewis (Trop2+) tumor-bearing mice.